Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
44,85 USD | +0,34% | -8,34% | -12,59% |
Attività
Gli Stati Uniti rappresentano il 70,1% delle vendite nette.
Numero di dipendenti: 34 100
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 46 159 | 100,0 % | 45 006 | 100,0 % | -2,50% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
70,1
%
| 31 828 | 69,0 % | 31 555 | 70,1 % | -0,86% |
International
28,3
%
| 13 497 | 29,2 % | 12 752 | 28,3 % | -5,52% |
Other
1,6
%
| 834 | 1,8 % | 699 | 1,6 % | -16,19% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Chief Executive Officer | 53 | 01/02/15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/11/19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 01/01/03 | |
Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/01/19 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/11/19 |
Laura Hortas
IRO | Public Communications Contact | - | - |
Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20/11/19 |
Peter Arduini
BRD | Director/Board Member | 59 | 01/04/16 |
Derica Rice
BRD | Director/Board Member | 59 | 01/09/20 |
Paula Price
BRD | Director/Board Member | 62 | 01/09/20 |
Theodore Samuels
BRD | Director/Board Member | 69 | 21/02/17 |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/11/19 |
Chief Executive Officer | 53 | 01/02/15 | |
Julia Haller
BRD | Director/Board Member | 69 | 20/11/19 |
Deepak Bhatt
BRD | Director/Board Member | 56 | 14/06/22 |
Karen Vousden
BRD | Director/Board Member | 66 | 01/01/18 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 2 923 100 096 | 2 024 582 731 ( 69,26 %) | 896 000 000 ( 30,65 %) | 69,26 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
5 075 304 | 6.37% | 129 521 758 $ | |
KURA ONCOLOGY, INC. 1.80% | 1 370 171 | 1.80% | 29 225 747 $ |
UNIQURE N.V. 4.99% | 2 388 108 | 4.99% | 12 418 162 $ |
COMPUGEN LTD. 5.31% | 4 757 058 | 5.31% | 12 273 210 $ |
CELULARITY INC. 5.49% | 1 195 327 | 5.49% | 6 251 560 $ |
Coordinate società
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. |
Pharmaceuticals: Major
|
Celgene Alpine Investment Co. LLC
| |
Bristol-Myers Squibb SARL
Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France. |
Medical Distributors
|
Bristol-Myers Squibb Holdings Ireland Unlimited Co.
Bristol-Myers Squibb Holdings Ireland Unlimited Co. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Holdings Ireland Unlimited Co., a subsidiary of Bristol Myers Squibb Co., is a company headquartered in Ireland that operates as a holding company which develops medicines for serious diseases. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb Australia Pty Ltd.
Bristol-Myers Squibb Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Australia Pty Ltd. is a biopharmaceutical company that researches, develops and markets medicines for serious diseases. The company was founded in 1930 and is headquartered in Noble Park North, Australia. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb (Finland) Oy Ab
Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The private company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020. |
Pharmaceuticals: Generic
|
Bristol-Myers Squibb Belgium SA
Bristol-Myers Squibb Belgium SA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Belgium SA develops, manufactures and distributes medicines. The private company is based in Watermael-Boitsfor, Belgium. The CEO of the Belgian company is Paul Lacante. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb de México S de RL de CV
Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The private company is located in Mexico. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb AB
Bristol-Myers Squibb AB Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb AB is a private company that wholesales medical equipment and pharmacy. The company is based in Solna, Sweden. |
Medical Distributors
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-12,59% | 90,92 Mrd | |
+25,83% | 661 Mrd | |
+27,00% | 566 Mrd | |
-6,76% | 352 Mrd | |
+20,34% | 332 Mrd | |
+3,00% | 283 Mrd | |
+13,09% | 231 Mrd | |
+5,46% | 200 Mrd | |
-9,61% | 195 Mrd | |
-6,26% | 145 Mrd |
- Borsa valori
- Azioni
- Azione BMY
- Società Bristol-Myers Squibb Company